Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.

Ren JingNan WuYang WuQian ZhangQiankun LiangPeng Huang Shijian Yi

Published in: The Journal of clinical endocrinology and metabolism (2024)

CAB60, LEN, and apatinib are promising topical MKIs with statistically significant primary outcomes in RAIR-DTC patients, while CAB and anlotinib are effective in prolonging PFS in aMTC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
metabolic syndrome
patient reported outcomes
adipose tissue
insulin resistance